Ocuphire Pharma News

Ocuphire Pharma | 424B3: Prospectus

Feb 17 05:33

Ocuphire Pharma | EFFECT: Others

Jan 24 19:04

Ocuphire Pharma | 424B5: Prospectus

Aug 14, 2023 20:00

Ocuphire Pharma | 424B5: Prospectus

Jun 8, 2021 04:21

Ocuphire Pharma | 424B5: Prospectus

Mar 11, 2021 22:19

Ocuphire Pharma | 424B4: Prospectus

Feb 17, 2021 20:14

Ocuphire Pharma | EFFECT: Others

Feb 16, 2021 13:19

Ocuphire Pharma | 425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions

Nov 3, 2020 19:04

Ocuphire Pharma | 425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions

Oct 20, 2020 20:55

Ocuphire Pharma | 425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions

Oct 17, 2020 04:01

Ocuphire Pharma | 425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions

Oct 10, 2020 04:01

Ocuphire Pharma | EFFECT: Others

Oct 5, 2020 12:21

Ocuphire Pharma | 424B3: Prospectus

Oct 2, 2020 21:25

Ocuphire Pharma | S-4/A: Registration of securities issued in business combination transactions (Amendment)

Sep 30, 2020 21:17

Ocuphire Pharma | S-4/A: Registration of securities issued in business combination transactions (Amendment)

Sep 16, 2020 09:50

Ocuphire Pharma | S-4/A: Registration of securities issued in business combination transactions (Amendment)

Aug 28, 2020 05:04

Ocuphire Pharma | S-4: Registration of securities issued in business combination transactions

Jul 7, 2020 04:08

Ocuphire Pharma | 425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions

Jul 1, 2020 20:35

Ocuphire Pharma | 425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions

Jun 19, 2020 21:00

Ocuphire Pharma | 425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions

Jun 18, 2020 21:14